Tesamorelin Dosage Protocol: Daily Dosing, Fat-Loss Timing, and Cycle Length (2026 Guide)

Tesamorelin Dosage at a Glance: What the Clinical Data Actually Says

Tesamorelin dosage for fat loss ranges from 1 mg to 2 mg daily by subcutaneous injection, depending on formulation and goal. The FDA-approved Egrifta SV dose is 1.4 mg once daily; off-label body-composition use typically runs 1–2 mg at bedtime. Phase 3 clinical trials confirm 15–18% visceral adipose tissue reduction over 26 weeks. Falutz 2010

Tesamorelin is the only FDA-approved growth hormone releasing hormone (GHRH) analog on the market. Unlike direct GH injections, it works upstream: it signals your pituitary to release its own endogenous growth hormone in pulsatile waves, preserving the natural feedback loop that keeps IGF-1 in check. NIH LiverTox 2018

This guide covers the standard clinical dose, an off-label body-composition dosing framework, a practical dose chart by goal, the optimal injection timing for fat loss, reconstitution protocol, side-effect profile, and stacking notes with CJC-1295 and ipamorelin. Every recommendation is anchored to Phase 3 trial data or FDA labelling. Nothing here is medical advice; always work with a qualified clinician before making changes to your health protocol.

Affiliate disclosure: This post contains links to research-grade peptide vendors. We maintain a vendor-neutral recommended-sources list. See our sources page for current vetted suppliers.

What Is Tesamorelin and Why Does Dosage Matter?

Tesamorelin is a 44-amino acid synthetic analog of GHRH with a trans-3-hexenoic acid modification at the N-terminus that protects it from rapid degradation by serum DPP-4 enzyme. This structural change extends its half-life to roughly 26–38 minutes in circulation, compared with just a few minutes for native GHRH. Getting the dose right determines whether you reach the pulsatile GH threshold needed for visceral fat oxidation. NIH LiverTox 2018

Because tesamorelin acts on GHRH receptors rather than bypassing the pituitary entirely, the dose-response curve is more nuanced than with direct GH. Too little and you fail to meaningfully elevate IGF-1. Too much, for too long without cycling, and pituitary receptor downregulation blunts your returns. The clinical sweet spot documented across multiple Phase 3 trials sits between 1 mg and 2 mg daily. Stanley 2011

See the tesamorelin peptide hub for mechanism background before diving into the dosing detail.

FDA-Approved Tesamorelin Dose vs Off-Label Body-Composition Dosing

The FDA-approved dose depends on formulation: 2 mg daily for original Egrifta, 1.4 mg daily for Egrifta SV, and 1.28 mg daily for Egrifta WR, all by once-daily subcutaneous injection. Off-label research protocols for body composition typically use 1–2 mg nightly, often beginning at 1 mg for the first week to establish tolerability before stepping up to 2 mg. These off-label doses mirror the Phase 3 trial arms that demonstrated visceral fat reduction. FDA Egrifta SV Label 2024

The original FDA approval in 2010 used 2 mg daily based on Phase 3 RCT data that showed ~18% visceral adipose tissue reduction over 26 weeks. The Egrifta SV reformulation consolidated the dose to 1.4 mg owing to improved bioavailability in the new formulation. Off-label compounding pharmacy preparations frequently use 2 mg vials reconstituted with 2.5 mL bacteriostatic water to yield a 0.8 mg/mL concentration, allowing precise dose titration. FDA Egrifta Original Label 2010

Important: the FDA indication is specifically HIV-associated lipodystrophy. Off-label use for general body composition in non-HIV individuals lacks the same regulatory trial base. Phase 3 mechanisms are clearly translatable, but individual response varies by metabolic baseline. Grunfeld 2015

Tesamorelin Dosage Chart by Goal

The right tesamorelin dose depends on your starting point, primary goal, and risk tolerance. The chart below summarises the three main tiers documented in clinical evidence and off-label research protocols. Each tier uses once-daily subcutaneous injection, ideally at bedtime. Always confirm dosing with a qualified clinician before starting. Dhillon 2012

Response predictors from Phase 3 pooled analysis (n=806): metabolic syndrome, triglycerides above 150 mg/dL, and elevated baseline visceral adipose tissue all correlate with stronger responses. If you fit these metabolic markers, you are more likely to see the upper-range 18% VAT reduction. Grunfeld 2015 PMC

Daily Timing for Fat Loss: Why Bedtime Beats Morning

Bedtime injection, at least two hours after your last meal, is the optimal timing for tesamorelin because it aligns GHRH stimulation with the body's natural nocturnal growth hormone surge. GH secretion in healthy adults is highest in the first few hours of slow-wave sleep. Tesamorelin amplifies this pulse rather than creating an artificial flat-line elevation, which matters for both efficacy and receptor preservation. Falutz 2010

The fasting state matters because elevated insulin directly suppresses GH secretion at the pituitary level. If you inject immediately after a carbohydrate-rich meal, the insulin environment blunts the GH pulse tesamorelin triggers. A two-hour minimum post-meal window is a practical floor; four hours post-dinner is ideal if your schedule allows. DailyMed Egrifta SV 2024

Morning injection is not contraindicated in FDA labelling, but clinical trial administration predominantly used evening dosing aligned with the nocturnal GH surge. For body-composition goals, the bedtime protocol is standard in off-label clinical practice.

Visceral Fat Loss Protocol and Realistic Timeline

Tesamorelin's visceral fat reduction is well-documented but takes time. Clinical Phase 3 data show roughly 15–18% visceral adipose tissue reduction over 26 weeks of continuous daily use, with reductions maintained through 52 weeks. Subjective waist changes typically begin around weeks 8–12; measurable VAT reduction on imaging by weeks 12–16. Expecting visible change in week two is unrealistic and not supported by trial data. Dhillon 2012

A realistic fat-loss timeline:

• Weeks 1–2: Titration period; possible mild water retention as IGF-1 rises. No visible fat change expected.
• Weeks 4–8: IGF-1 levels elevate to roughly 30–80% above baseline. Early metabolic shifts; some individuals report reduced abdominal bloating.
• Weeks 8–16: First visible waist circumference reduction. Liver enzyme improvements in responders. Guaraldi 2017
• Weeks 16–26: Peak VAT reduction in clinical responders; metabolic markers (triglycerides, hepatic fat) improve. Capeau 2015
• Weeks 26–52: Maintenance of achieved reduction if dosing continues. Discontinuation leads to VAT reaccumulation within weeks to months.

One critical point: visceral fat returns after you stop. This is not a one-cycle fix. Phase 3 data confirm that VAT reaccumulates within months of discontinuation, meaning continued use or a structured maintenance protocol is required to sustain the benefit. Falutz 2010

The 2023 analysis of INSTI-treated patients confirms greater than 15% VAT reduction over six months in a contemporary cohort, reinforcing that the Phase 3 findings translate beyond the original HIV-HAART population. Falutz 2023

Cycle Length, Titration, and Maintenance Protocol

Tesamorelin is supported by clinical data through 52 weeks of continuous use, but continuous uninterrupted GHRH stimulation risks pituitary GHRH-receptor downregulation over longer windows. Off-label practice typically structures 12–16 week active phases followed by 4–8 week rest periods, or a 5-days-on, 2-days-off weekly pattern to preserve pituitary sensitivity. Maintenance dosing at 1–1.4 mg nightly can sustain VAT reduction with less receptor load than the full induction dose. Stanley 2012

Titration framework:

• Week 1 (titration): 1 mg nightly to establish tolerability and assess injection site response.
• Weeks 2–12 (induction): 1.4–2 mg nightly; primary fat-loss phase.
• Weeks 12–26 (consolidation): Continue 1.4–2 mg or step down to 1 mg if IGF-1 is running high.
• Weeks 26+ (maintenance or rest): Structured break of 4–8 weeks or shift to 5-on/2-off protocol at reduced dose.

IGF-1 monitoring is the key safety checkpoint. The FDA recommends discontinuing tesamorelin if IGF-1 persistently exceeds the age-adjusted upper limit of normal. Get a baseline IGF-1 before starting and recheck at 12 weeks. FDA Egrifta Label 2025

Reconstitution and Subcutaneous Injection Technique

Tesamorelin reconstitution requires bacteriostatic water for multi-vial research preparations (2.5 mL per 2 mg vial yields a 0.8 mg/mL concentration) or 0.5 mL sterile water for Egrifta SV (2.8 mg/mL final). Inject the diluent slowly down the inside of the vial wall, then roll gently for 30 seconds. Never shake. Shaking denatures peptide bonds and degrades potency. FDA Egrifta SV Label 2024

Step-by-step reconstitution:

1. Wipe the vial septum and your chosen diluent vial with an alcohol swab; allow to dry.
2. Draw the correct volume of bacteriostatic water into a 1 mL insulin syringe.
3. Insert the needle at a 45-degree angle into the tesamorelin vial; release the diluent slowly against the glass wall, not directly onto the lyophilised powder.
4. Remove the needle and roll the vial gently between your palms for 30 seconds until the powder is fully dissolved. Solution should be clear and colourless.
5. Inspect visually: discard if particulate matter or cloudiness is present.
6. Draw your calculated dose into a fresh insulin syringe.

Injection site: the abdomen only, per FDA labelling. Rotate sites within the abdominal quadrants with each injection to avoid lipohypertrophy. Avoid the navel, scar tissue, bruised areas, or the waistband line. Pinch a small skin fold, insert at 45–90 degrees depending on subcutaneous depth, and inject slowly. FDA Egrifta SV Label 2024

For a full visual guide to subcutaneous technique and site rotation, see our tesamorelin reconstitution with bacteriostatic water guide.

Side Effects: What Clinical Trials Actually Reported

The most common adverse events from Phase 3 tesamorelin trials are injection site reactions (pruritus and erythema in roughly 8–13% of users versus 5–7% placebo), peripheral oedema at 6.1% versus 2.3% placebo, and musculoskeletal discomfort including joint pain and carpal tunnel symptoms. Serious adverse events occurred at statistically similar rates between tesamorelin and placebo groups, which is reassuring across a 52-week window. Falutz Trial Protocol 2023

Key metabolic risks to monitor:

• Diabetes / glucose: HbA1c above 6.5% occurred in 5% of tesamorelin patients versus 1% placebo (hazard ratio 3.3). Pre-diabetic individuals require baseline and periodic HbA1c monitoring. FDA Egrifta Label 2025
• IGF-1 elevation: Expected ~47% above upper limit of normal at 26 weeks in clinical trials. Supraphysiological IGF-1 over extended periods carries theoretical proliferative risk; IGF-1 testing at 12-week intervals is standard practice. FDA Egrifta Label 2025
• Anti-tesamorelin antibodies: Develop in approximately 47–50% of patients after 26–52 weeks. Roughly 60% of antibody-positive patients show cross-reactivity with endogenous GHRH. In most cases this does not reduce efficacy, but it is a monitoring consideration for long-term users. FDA Egrifta Label 2025
• Fluid retention: Peripheral oedema, arthralgias, and carpal tunnel syndrome are GH-class effects; they typically resolve with dose reduction or cessation.

Absolute contraindications: active malignancy of any type, pregnancy or breastfeeding, known hypersensitivity to tesamorelin or mannitol, and use in children with open epiphyses. FDA Egrifta SV Label 2024

Phase 2b data in type 2 diabetics (tesamorelin 1–2 mg) found favourable tolerability with no significant worsening of glucose control compared with placebo, which is cautiously reassuring for metabolically compromised users, but always work with a qualified clinician before making changes to your health protocol. Stanley 2017

Stacking Tesamorelin with CJC-1295 and Ipamorelin

Tesamorelin and ipamorelin target complementary receptor pathways: tesamorelin activates pituitary GHRH receptors while ipamorelin activates ghrelin/GHS-R1a receptors. These mechanisms are additive rather than redundant, which is why the CJC-1295 and ipamorelin stack is the most common GH-axis combination in off-label research practice. However, running full doses of two GHRH analogs concurrently (tesamorelin plus CJC-1295) provides minimal additional benefit and increases receptor saturation risk. Stanley 2012

Practical stacking approaches:

• Tesamorelin + ipamorelin: The most evidence-supported off-label pairing. Tesamorelin provides sustained GHRH-receptor activation for visceral fat oxidation; ipamorelin provides complementary GHRP-pathway GH pulses without significantly elevating cortisol or prolactin. Typical pairing: 1–2 mg tesamorelin nightly with 100–200 mcg ipamorelin at the same injection time. See the ipamorelin dosing and stacking with tesamorelin guide for full ipamorelin protocol detail.
• Tesamorelin vs CJC-1295: Both are GHRH analogs; choosing one as your primary GHRH agent and using ipamorelin as the GHRP is more rational than stacking two GHRH analogs. CJC-1295 without DAC has a shorter half-life and more pulsatile action; CJC-1295 with DAC has a long half-life and continuous elevation. For fat-loss prioritisation, tesamorelin's Phase 3 evidence base makes it the stronger primary choice. See the CJC-1295 comparison and stacking strategy guide.
• Alternating cycles: A common structured approach cycles 12 weeks of tesamorelin followed by 12 weeks of CJC-1295 with ipamorelin, preserving receptor sensitivity to both analog classes across the year.

Monitoring Labs and Decision Points

Baseline and on-cycle monitoring is not optional for responsible tesamorelin use. The minimum lab panel before starting should include IGF-1, HbA1c, fasting glucose, and a lipid panel. At 12 weeks, recheck IGF-1 and HbA1c. At 26 weeks, full metabolic panel. If IGF-1 exceeds the age-adjusted upper limit of normal on two consecutive tests, the FDA recommends discontinuation until levels normalise. FDA Egrifta Label 2025

Decision points:

• IGF-1 persistently elevated above age-adjusted normal: reduce dose or pause.
• HbA1c creeping above 6.0%: review dietary carbohydrate load and consult your clinician about continuation.
• Significant peripheral oedema that does not resolve in two to four weeks: reduce dose by 50% or pause.
• At week 26: assess whether you are a responder (VAT reduction above 8%). Non-responders at this point are unlikely to benefit from continued use per Phase 3 data. Grunfeld 2015 PMC

Always work with a qualified clinician before making changes to your health protocol. Lab panels can be ordered through independent telemedicine services; your prescribing physician should review IGF-1 and HbA1c trends before you extend beyond a 12-week initial run.

Where to Source Research-Grade Tesamorelin

Sourcing quality matters enormously for peptide efficacy and safety. A vial labelled 2 mg tesamorelin can contain anything from 1.1 mg to 2.4 mg of actual peptide depending on vendor QC practices, with some third-party tests showing contamination levels that nullify the dose-response expectations from Phase 3 trials. Vendor selection should always be anchored to HPLC purity testing and independent COA verification. Dhillon 2012

We maintain a vetted, vendor-neutral recommended-sources list updated quarterly. See our recommended sources page for current suppliers with verified third-party testing. Never purchase from vendors who cannot provide batch-specific HPLC and mass spectrometry reports.

References

• FDA. EGRIFTA SV Full Prescribing Information. 2024.
• FDA. EGRIFTA Full Prescribing Information. 2025.
• FDA. EGRIFTA Original Approval Label. 2010.
• Falutz J et al. Effects of tesamorelin in HIV-infected patients with abdominal fat accumulation. NEJM. 2010.
• Dhillon S. Tesamorelin: a review. Drugs. 2012.
• NIH LiverTox. Tesamorelin. 2018.
• Grunfeld C et al. Predictors of Treatment Response to Tesamorelin. JCEM. 2015.
• Grunfeld C et al. Predictors of Treatment Response to Tesamorelin. JCEM. 2015.
• Stanley T et al. Growth hormone and tesamorelin in HIV-associated lipodystrophy. Curr HIV/AIDS Rep. 2011.
• Stanley T. Spotlight on tesamorelin. Drugs Today. 2012.
• Guaraldi G et al. Visceral fat reduction with tesamorelin and liver enzymes in HIV. AIDS. 2017.
• Capeau J et al. Effect of Tesamorelin on Liver Fat and Visceral Fat in HIV. Clin Infect Dis. 2015.
• Stanley T et al. Safety and metabolic effects of tesamorelin in type 2 diabetes. Diabetes Care. 2017.
• Falutz J et al. Tesamorelin Reduces VAT and Liver Fat in INSTI-Treated Persons with HIV. 2023.
• DailyMed. EGRIFTA SV Label. 2024.

This content is for educational purposes only. These compounds are intended for research use. Nothing here is medical advice. Always work with a qualified clinician before making changes to your health protocol.